Vol. 23/No. 16 | OncologyLive

Tumor Agnostic Role of TMB Biomarker Faces Challenges

August 18, 2022

Oncology Nursing News

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease

August 15, 2022

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.